| Lymphoma, Non-Hodgkin

Rituxan vs Rayos

Side-by-side clinical, coverage, and cost comparison for lymphoma, non-hodgkin.

Deep comparison between: Rituxan vs Rayos with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsRayos has a higher rate of injection site reactions vs Rituxan based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Rayos but not Rituxan, including UnitedHealthcare

Category

Rituxan

Rayos

At A Glance

RouteIV infusion

ClassAnti-CD20 monoclonal antibody

RouteOral

FrequencyDaily

ClassCorticosteroid

Indications

Lymphoma, Non-Hodgkin
Chronic Lymphocytic Leukemia
Rheumatoid Arthritis
Granulomatosis with polyangiitis
Microscopic Polyarteritis
Pemphigus Vulgaris
Acute lymphocytic leukemia

Dermatitis, Atopic
Allergic rhinitis (disorder)
Serum Sickness
Dermatitis Herpetiformis
Contact Dermatitis
Exfoliative dermatitis
Mycosis Fungoides
Pemphigus
Erythema Multiforme
Congenital Adrenal Hyperplasia
Hypercalcemia
thyroiditis; nonsuppurative
Adrenal gland hypofunction
Crohn Disease
Ulcerative Colitis
Autoimmune hemolytic anemia
Anemia, Diamond-Blackfan
Immune thrombocytopenic purpura
Pure Red-Cell Aplasia
Acute leukemia
Lymphoma, Non-Hodgkin
Multiple Sclerosis
Cerebral Edema
Ophthalmia, Sympathetic
Uveitis
Chronic Obstructive Airway Disease
Aspergillosis, Allergic Bronchopulmonary
Aspiration pneumonitis
Asthma
Tuberculosis
Extrinsic allergic alveolitis
Bronchiolitis Obliterans Organizing Pneumonia
Idiopathic eosinophilic pneumonitis
Idiopathic Pulmonary Fibrosis
Pneumonia, Lipid
Sarcoidosis
Nephrotic Syndrome
Primary gout
Ankylosing spondylitis
Dermatomyositis
Polymyalgia Rheumatica
Arthritis, Psoriatic
Polychondritis, Relapsing
Rheumatoid Arthritis
Sjogren's Syndrome
Lupus Erythematosus, Systemic
Vasculitis
Trichinellosis
Tuberculosis, Meningeal

Dosing

Lymphoma, Non-Hodgkin 375 mg/m2 IV; weekly for 4 or 8 doses for relapsed/refractory low-grade or follicular NHL; Day 1 of each chemotherapy cycle for up to 8 doses for previously untreated follicular or DLBCL; every 8 weeks for 12 doses as single-agent maintenance.

Acute lymphocytic leukemia 375 mg/m2 IV for 6 total infusions in combination with LMB chemotherapy (two doses during each of the two induction courses, one dose during each of the two consolidation courses) for pediatric patients aged 6 months and older.

Chronic Lymphocytic Leukemia 375 mg/m2 IV the day prior to initiation of cycle 1 FC chemotherapy, then 500 mg/m2 on Day 1 of cycles 2-6 every 28 days.

Rheumatoid Arthritis Two 1,000 mg IV infusions separated by 2 weeks per course in combination with methotrexate; subsequent courses every 24 weeks (no sooner than 16 weeks); premedicate with methylprednisolone 100 mg IV 30 minutes prior to each infusion.

Granulomatosis with polyangiitis, Microscopic Polyarteritis Induction: 375 mg/m2 IV once weekly for 4 weeks with glucocorticoids; follow-up: two 500 mg IV infusions separated by 2 weeks, then 500 mg IV every 6 months based on clinical evaluation.

Pemphigus Vulgaris Two 1,000 mg IV infusions separated by 2 weeks in combination with a tapering course of glucocorticoids; then 500 mg IV at Month 12 and every 6 months thereafter or based on clinical evaluation.

All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.

Contraindications

—

Known hypersensitivity to prednisone or any excipient

Drug Interactions

538View drug interactions

1287View drug interactions

Adverse Reactions

Most common (>=25%) Infusion-related reactions, fever, lymphopenia, chills, infection, asthenia (in NHL); infusion-related reactions, neutropenia (in CLL)

Serious Fatal infusion-related reactions, severe mucocutaneous reactions, hepatitis B reactivation with fulminant hepatitis, progressive multifocal leukoencephalopathy, tumor lysis syndrome, sepsis, cardiovascular events, renal toxicity, bowel obstruction and perforation

Postmarketing Prolonged pancytopenia, fatal cardiac failure, progressive multifocal leukoencephalopathy, severe mucocutaneous reactions, pyoderma gangrenosum, bowel obstruction and perforation, fatal bronchiolitis obliterans, fatal interstitial lung disease, posterior reversible encephalopathy syndrome

Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain

Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure

Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone

Pharmacology

Rituximab is a chimeric murine/human IgG1 kappa monoclonal antibody that binds the CD20 antigen on pre-B and mature B-lymphocytes, mediating B-cell lysis via complement dependent cytotoxicity (CDC) and antibody dependent cell mediated cytotoxicity (ADCC).

Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Rituxan